Risk Factors for and Trends in Isoniazid Monoresistance at Diagnosis of Tuberculosis—United States, 1993-2016
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Help
Clear All

Query Builder

Query box

Help
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Risk Factors for and Trends in Isoniazid Monoresistance at Diagnosis of Tuberculosis—United States, 1993-2016

Filetype[PDF-900.46 KB]


  • English
    • Details Supporting Files You May Also Like

    Details:

    • Alternative Title:
      J Public Health Manag Pract
    • Personal Author:
    • Description:
      Context

      Resistance to isoniazid (INH) only (monoresistance), with drug susceptibility to rifampin, pyrazinamide, and ethambutol at diagnosis of tuberculosis (TB) disease, can increase the length of treatment.

      Objective

      To describe US trends in INH monoresistance and associated patient characteristics.

      Design

      We performed trend and cross-sectional analyses of US National Tuberculosis Surveillance System surveillance data. We used Joinpoint regression to analyze annual trends in INH monoresistance and logistic regression to identify patient characteristics associated with INH monoresistance.

      Participants

      Culture-positive cases reported to National Tuberculosis Surveillance System during 1993–2016 with drug susceptibility test results to INH, rifampin, pyrazinamide, and ethambutol.

      Main Outcome Measures

      (1) Trends in INH monoresistance; (2) odds ratios for factors associated with INH monoresistance.

      Results

      Isoniazid monoresistance increased significantly from 4.1% of all TB cases in 1993 to 4.9% in 2016. Among US-born patients, INH monoresistance increased significantly from 2003 onward (annual percentage change = 2.8%; 95% confidence interval: 1.4–4.2). During 2003–2016, US-born persons with INH-monoresistant TB were more likely to be younger than 65 years; to be Asian; to be human immunodeficiency virus–infected; or to be a correctional facility resident at the time of diagnosis. Among non–US-born persons, INH resistance did not change significantly during 1993–2016 (annual percentage change = −0.3%; 95% confidence interval: −0.7 to 0.2) and was associated with being aged 15 to 64 years; being Asian, black, or Hispanic; or having a previous history of TB.

      Conclusions

      INH-monoresistant TB has been stable since 1993 among non–US-born persons; it has increased 2.8% annually among US-born persons during 2003–2016. Reasons for this increase should be further investigated.

    • Subject:
    • Source:
      J Public Health Manag Pract. 27(4):E162-E172
    • Pubmed ID:
      31688735
    • Pubmed Central ID:
      PMC7190402
    • Document Type:
      Journal Article
    • Funding:
      CC999999/ImCDC/Intramural CDC HHS/United States
    • Collection(s):
      CDC Public Access
    • Main Document Checksum:
    • File Type:

    You May Also Like

    Checkout today's featured content at stacks.cdc.gov